Applied Therapeutics, Inc.
NASDAQ:APLT
0.4401 (USD) • At close May 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.455 | 9.993 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.425 | 0.353 | 0.441 | 0.415 | 0.38 | 0.023 | 0 | 0 |
| Gross Profit
| 0.03 | 9.64 | -0.441 | -0.415 | -0.38 | -0.023 | 0 | 0 |
| Gross Profit Ratio
| 0.066 | 0.965 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 48.744 | 53.905 | 55.634 | 62.57 | 61.788 | 32.35 | 11.471 | 3.703 |
| General & Administrative Expenses
| 56.01 | 20.623 | 27.316 | 43.048 | 32.678 | 13.232 | 2.047 | 0.582 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 56.01 | 20.623 | 27.316 | 43.048 | 32.678 | 13.232 | 2.047 | 0.582 |
| Other Expenses
| 0 | 0 | -0.177 | -0.521 | -0.054 | -0.024 | -1.14 | 0 |
| Operating Expenses
| 104.754 | 74.528 | 82.95 | 105.618 | 94.466 | 45.582 | 13.518 | 4.285 |
| Operating Income
| -104.299 | -64.535 | -82.95 | -105.618 | -94.466 | -45.582 | -13.518 | -4.285 |
| Operating Income Ratio
| -229.229 | -6.458 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -1.325 | -55.228 | 0.442 | 0.034 | 0.505 | 0.069 | -3.003 | 0.003 |
| Income Before Tax
| -105.624 | -119.763 | -82.508 | -105.584 | -93.961 | -45.513 | -16.521 | -4.282 |
| Income Before Tax Ratio
| -232.141 | -11.985 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | -0.819 | -0.97 | -0.939 | -0.116 | 4.866 | -4.285 |
| Net Income
| -105.624 | -119.763 | -81.689 | -104.614 | -93.022 | -45.397 | -16.521 | -4.282 |
| Net Income Ratio
| -232.141 | -11.985 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.76 | -1.42 | -2.16 | -4.09 | -4.23 | -3.54 | -1.8 | -0.47 |
| EPS Diluted
| -0.76 | -1.42 | -2.16 | -4.09 | -4.23 | -3.54 | -1.8 | -0.47 |
| EBITDA
| -103.873 | -64.534 | -82.067 | -105.169 | -94.466 | -45.582 | -3.003 | 0.003 |
| EBITDA Ratio
| -228.292 | -6.458 | 0 | 0 | 0 | 0 | 0 | 0 |